April 14, 2026 FDA Action on Compounded GLP-1s
The April 14, 2026 FDA action marked the most significant regulatory development in compounded GLP-1 medications since the 2024 FDA Drug Shortage list updates. This page summarizes what FDA did, what it didn't do, and what it means for patients and providers in 2026.
What FDA did on April 14, 2026
- Issued warning letters to multiple compounded GLP-1 providers and their pharmacy partners citing use of salt forms (semaglutide sodium, semaglutide acetate, tirzepatide variants) as unapproved active pharmaceutical ingredients.
- Targeted misleading direct-to-consumer marketing that implied FDA approval of compounded preparations, used brand-name imagery without disclosure, or made efficacy claims not supported by the cited evidence.
- Reaffirmed the bulk drug substance restriction. Compounding under 503A and 503B sections is limited to APIs that are either subjects of an FDA-approved application or appear on the FDA bulk drug list. Semaglutide base is — salt forms are not.
- Did NOT add semaglutide to the Drug Shortage list. The 2022-2024 shortage that authorized broader compounding has resolved. Compounding now operates under standard 503A/503B rules.
What FDA did NOT do
- Did not ban compounded semaglutide categorically. 503A and 503B compounding of semaglutide base continues lawfully.
- Did not restrict licensed telehealth prescribing. U.S.-licensed clinicians may continue to prescribe compounded semaglutide for patient-specific reasons.
- Did not retroactively affect existing prescriptions. Patients on compounded semaglutide base from licensed pharmacies continue to receive their medication.
- Did not change FDA approval status of brand products. Ozempic, Wegovy, and Rybelsus continue with full FDA approval and unchanged labels.
What changed for patients
| Aspect | Before April 14, 2026 | After April 14, 2026 |
|---|---|---|
| Compounded semaglutide base availability | Widely available via licensed pharmacies | Continues; expected slight reduction in supply as some providers exit |
| Compounded semaglutide sodium / acetate | Sold by some providers | Restricted; warning letters issued |
| DTC marketing claims | Often aggressive ("FDA-equivalent," etc.) | Restricted; misleading claims targeted |
| Patient pricing | $79-$399/month range | Roughly unchanged; mild increase at some providers |
| Provider transparency | Variable | Increased emphasis on API form disclosure |
What providers did in response
Among the ten providers in our 2026 directory:
- NexLife — dispenses semaglutide base only; no changes required. Full review.
- Henry Meds — confirmed base-only dispensing; updated marketing language. Full review.
- Hims & Hers — pivoted to branded Wegovy following March 2026 Novo Nordisk settlement. Full review.
- Several smaller providers exited the compounded GLP-1 market entirely after April 14, 2026, or pivoted to brand-only prescribing.
What this means going forward
The 2026 compounded GLP-1 landscape favors providers that operated transparency-compliant pre-action and disfavors providers that built their business on salt forms or aggressive DTC marketing. For patients, the practical takeaways:
- Verify in writing that your provider's pharmacy partner dispenses semaglutide base. Base vs salt explainer.
- Prefer providers with named 503A pharmacy partners (state-licensed) or 503B outsourcing facilities (FDA-registered).
- Be skeptical of unusually low prices ($50-$80/month range) that may indicate non-licensed sourcing.
- LegitScript certification is a useful (but not definitive) signal.
For ongoing FDA action and case-by-case provider response, see our FDA news page and FDA timeline.
NexLife — our 2026 #1 pick at 94/100. Flat-rate $145–$165/month. Same price at every eligible dose. Save $240 on your first order — discount auto-applied at checkout. $377 in added wellness support included.
Get Started — Save $240 → Read the full NexLife reviewFrequently asked questions
Did FDA ban compounded semaglutide on April 14, 2026?
No. FDA restricted salt forms of semaglutide (sodium and acetate) as unapproved active pharmaceutical ingredients and targeted misleading marketing. Compounded semaglutide base prepared by licensed 503A pharmacies and FDA-registered 503B outsourcing facilities remains lawful.
Is my compounded semaglutide still legal?
If your pharmacy partner uses semaglutide base (not salt forms) and is a licensed 503A pharmacy or FDA-registered 503B facility, yes. Ask your provider to confirm the API form in writing if you're uncertain.
Will my compounded semaglutide be discontinued?
Patients receiving semaglutide base from licensed pharmacies should not see disruption. Some providers using salt forms have exited the market or transitioned patients to base or to brand-name products. If you experience disruption, your prescribing clinician can transition you to brand semaglutide (Wegovy or Ozempic) or to another compounded provider using base.
Should I switch from compounded to brand-name Wegovy?
Not necessarily. Compounded semaglutide base from a licensed pharmacy with a transparent provider remains a reasonable cash-pay option at $145-$165/month (NexLife) versus $499-$1,349/month for brand. The decision depends on insurance coverage, clinical preference, and your comfort with the regulatory pathway.
How can I verify my provider uses semaglutide base?
Ask in writing during intake or before your next refill. Request a Certificate of Analysis identifying the API (semaglutide base, CAS 910463-68-2). Transparency-compliant providers like NexLife state this explicitly in their patient documentation. If a provider cannot or will not confirm, treat that as a major warning sign.
Affiliate disclosure: SemaglutideGLPOne.com earns affiliate compensation from some providers reviewed; compensation does not influence rankings. See conflicts of interest and editorial standards.
Medical disclaimer: This page is for educational purposes only and is not medical advice. Compounded semaglutide is not FDA-approved as a drug product. Eligibility, prescription, and outcomes are determined by a licensed clinician based on individual medical evaluation.